Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3 - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue European Journal of Haematology Année : 2023

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3

Résumé

We describe the case of a patient with extreme thrombocytosis whose evolution was rapidly fatal. No cause of secondary thrombocytosis was found. There was no sign of myelofibrosis but the megakaryocytes were small and dysplastic. The patient presented a calreticulin (CALR) variant in exon 3 (C105S), as well as concomitant mutations of ASXL1, U2AF1, and EZH2. This variant of CALR has never been described before, and after sorting, all identified mutations were found in myeloid cells but not in lymphoid cells. Therefore, the diagnosis of a frontier case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) was made. A treatment with hydroxycarbamide was started because of a high risk of thrombosis. Upon worsening of the hematological status two new mutations appeared, SETBP1 and ETV6, and the CALR mutation was still detectable, as well as the three other mutations found in the chronic stage. Our results show that this variant could contribute to MDS/MPN pathogenesis in that patient.

Dates et versions

hal-04550049 , version 1 (17-04-2024)

Identifiants

Citer

Sarah Bonnet, Serge Carillo, Baptiste Legrand, Barbara Burroni, Thierry Lavabre-Bertrand, et al.. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3. European Journal of Haematology, 2023, 112 (3), pp.475-478. ⟨10.1111/ejh.14126⟩. ⟨hal-04550049⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More